| 摘要 |
<p>Carboxyl terminal fragments of PTHrP also known by the name adenylate cyclase stimulating factor [ACSF] and bone releasing factor [BRF] are shown to possess bone resorption inhibitory activity which is an opposite activity to that embodied by the complete PTHrP sequence and N-terminal fragments thereof. There is described compounds having bone resorption inhibitory activity which comprise carboxy terminal fragment of PTHrP consisting of at least amino acids 107-111 of PTHrP, or a derivative thereof. Methods for the inhibition of bone resorption, and methods for the treatment of diseases characterised by excess bone resorption are also described, which methods comprise administering to a subject in need of such treatment a bone resorption inhibitory effective amount of a carboxy terminal fragment of PTHrP consisting of at least amino acids 107-111 of PTHrP or a derivative thereof optionally in association with a pharmaceutically acceptable carrier or excipient.</p> |
